NUVISAN has a long history of servicing the pharmaceutical and Biotechnology companies. Having started over 40 years ago with a Bioanalytical lab to a complete panel of services our company is now a sound partner to over 200 corporations at all development stages.
The broad portfolio of solutions provided by NUVISAN has helped develop strong partnerships, from the top 10 pharmaceutical companies to the biotech newly settled, adapting to the needs and regulatory requirements identified.
Our team of scientist strive in supporting our business partners throughout the complex drug development process, by developing fast and maximising the value of our partners IP and assets they put in our hands.
With over 400 scientists supporting this side of the drug development, backed by one of the strongest technological platform in Europe, our newly running entity, in central Berlin – Germany, can deliver.
The platform which has been running for many years to the benefit of a major pharmaceutical player is now available to All. From Target Identification to Candidate selection under GLP, through to hit identification, hit-to-lead and Lead optimization our people have shown through the years the ability to create true collaboration with our partners, focusing and creating value.
We have focused in delivering turnkey solution to our collaborator, from the single isolated study to the large corporate collaboration the projects are driven by seasoned industry scientist providing advice and support through well though process.
We can deliver from DMPK Research through to development and safety assessment studies, with in vitro and in vivo facilities.
NUVISAN was built around laboratory services and our platform is now available in different locations throughout Europe. Our GxP facilities can assess pretty much all sort of test items, in different matrices.
Our Bioanalytical lab goes from proof of exposure to biomarkers research and development with a broad range of technologies (see platform here), from early research to late stage clinical trials, primary and secondary endpoints.
Our Analytical platform can support from SME to large molecules, and from early set-up to complete bioassays in large sample volumes.
Several clinical testing facilities are available to support and perform healthy volunteers with a complete set of backend services to provide a comprehensive solution. Our phase 1 units can deliver from First-in-Man to Drug-Drug interaction, BioEquivalence, PK and many other study subtypes.
Our advance methodologies for Volunteers recruitment and backed by many medics allows for a comprehensive and time-efficient execution.
NUVISAN has a long history of full integration of the drug substance and drug product services through Pharmaceutical Analysis and release testing, GMP API process development, upscaling and synthesis and Drug Formulation development and production services
NUVISAN can support API supply to the pharmaceutical industry through its pilot plant with the support of 10s of PhD level organic chemists. With the capacity to produce for the gram scale to the 5-10kg batches our laboratory can support and drive the full process with the supporting analytics (solid form characterization and impurity profiling) required to guarantee the best available quality standards.
NUVISAN can also support the formulation of the API into a Drug product across Europe and our teams of formulation scientists will be he to work jointly with the chemist to deliver the formulated product at all stages of the development.
Our Pharmaceutical Analysis and release testing teams are available across Europe and follow the GMP process to produce all requested testing, from stability through to microbiology and many more, for both drug and reference products.
As good logistics are essential to the good conduct of your clinical development projects. NUVISAN provide a vast capacity of services to support clinical trial.
From manufacturing, primary to secondary packaging and distribution with our many Qualified Persons NUVISAN can support the full set of services to support from Phase 1 to 3.